AbbVie, Iambic collaborate on AI-driven drug discovery
AbbVie Inc. and Iambic have announced a collaboration aimed at accelerating small molecule drug discovery in immunology, neuroscience, and oncology using AI. Iambic will receive an upfront payment, milestone payments, and tiered royalties from the collaboration.
Sept 21 (Reuters) — AbbVie Inc. and Iambic said they have entered into a collaboration to accelerate AI-driven small molecule drug discovery in immunology, neuroscience and oncology. Iambic will receive upfront payment, milestone payments and tiered royalties from the collaboration.